Disease Modeling and Organoid Technology (DMOT) research group, Department of Dermatology, Medical University of Vienna, Austria.
J Dtsch Dermatol Ges. 2021 Jan;19(1):19-29. doi: 10.1111/ddg.14314.
Drug-induced photosensitivity, the development of phototoxic or photoallergic reactions due to pharmaceuticals and subsequent exposure to ultraviolet or visible light, is an adverse effect of growing interest. This is illustrated by the broad spectrum of recent investigations on the topic, ranging from molecular mechanisms and culprit drugs through epidemiological as well as public health related issues to long-term photoaging and potential photocarcinogenic consequences. The present review summarizes the current state of knowledge on the topic while focusing on culprit drugs and long-term effects. In total, 393 different drugs or drug compounds are reported to have a photosensitizing potential, although the level of evidence regarding their ability to induce photosensitive reactions varies markedly among these agents. The pharmaceuticals of interest belong to a wide variety of drug classes. The epidemiological risk associated with the use of photosensitizers is difficult to assess due to under-reporting and geographical differences. However, the widespread use of photosensitizing drugs combined with the potential photocarcinogenic effects reported for several agents has major implications for health and safety and suggests a need for further research on the long-term effects.
药物诱导的光敏性是指由于药物暴露于紫外线或可见光而引起的光毒性或光过敏反应，这是一种日益受到关注的不良反应。最近对该主题的广泛研究说明了这一点，研究范围从分子机制和罪魁祸首药物到流行病学以及与公共卫生相关的问题，再到长期光老化和潜在的光致癌后果。本综述总结了该主题的最新知识，重点介绍了罪魁祸首药物和长期影响。总共有 393 种不同的药物或药物化合物被报道具有光敏潜力，尽管这些药物诱导光敏反应的能力的证据水平差异很大。这些药物属于多种药物类别。由于报告不足和地理差异，很难评估与使用光敏剂相关的流行病学风险。然而，由于多种药物的广泛使用以及报道的几种药物具有潜在的光致癌作用，这对健康和安全有重大影响，并表明需要进一步研究长期影响。
